Javed Butler, MD, MBA, discusses how aldosterone synthase inhibition could shift treatment across heart failure, CKD, and resistant hypertension.

Javed Butler, MD, MBA, on Aldosterone & Aldosterone Synthase Inhibitors in Cardiology

Aldosterone is drawing renewed scientific attention as a treatment target across 

. A new generation of aldosterone synthase inhibitors aims to lower aldosterone production directly, rather than blocking its receptor.

, Javed Butler, MD, MBA, president of the Baylor Scott & White Research Institute, examined where this approach fits in cardiorenal care. He weighed the evidence behind aldosterone synthase inhibition and its potential role in guideline-directed medical therapy for heart failure.

Recapping a session he led at the meeting, Butler emphasized how earlier aldosterone modulation data came largely from heart failure with reduced ejection fraction, along with post-myocardial infarction trials in reduced ejection fraction and heart failure. Noting evidence in chronic kidney disease and in prevention lagged, and findings in heart failure with preserved ejection fraction were contested.

Butler highlighted the unresolved question remains whether the aldosterone hypothesis itself is flawed or whether current receptor-targeted therapies leave meaningful residual benefit unharnessed. Lowering aldosterone levels directly through synthase inhibition offers a way to test the second possibility.

When asked on choosing between mineralocorticoid receptor antagonists and aldosterone synthase inhibitors, Butler highlighted this debate remains unsettled until further trial data becomes available. He called attention to earlier MRA trials enrolling few patients on SGLT2 inhibitors or GLP-1 receptor agonists, whereas the synthase inhibitor trials use active comparators in which every participant receives an SGLT2 inhibitor.

ClinicalTrials.Gov. A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure (LUMINARA). Clinicaltrials.gov. Published February 18, 2026. Accessed June 21, 2026. https://clinicaltrials.gov/study/NCT06299826 

Videos

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Ralph DeFronzo, MD
Credit: UT Health San Antonio

 was nearly twice as common in individuals with resistant hypertension and an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² as in those with preserved kidney function, according to a kidney-stratified analysis of the MOMENTUM study presented at the 

The data come less than a week after Corcept Therapeutics announced the resubmission of its New Drug Application for relacorilant as a treatment for patients with hypercortisolism to the US Food and Drug Administration on June 17, 2026. This resubmission is based on the GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, relacorilant’s long-term extension study, and earlier-stage development data.

“MOMENTUM showed that individuals with rHTN and reduced kidney function have an elevated risk of HC, supporting the need for targeted screening in this high-risk population,” wrote investigators, who were led by Ralph DeFronzo, MD, of UT Health San Antonio. 

MOMENTUM (NCT06829537) is the first US-based trial to assess endogenous hypercortisolism in resistant hypertension, where the relationship between reduced kidney function and hypercortisolism has been poorly characterized. Funded by Corcept Therapeutics, the US, multicenter, prospective, observational study screened adults aged 18 years or older with resistant hypertension per American Heart Association criteria. 

The original study was presented by Deepak Bhatt, MD, MPH, MBA, of Mount Sinai, as a late-breaker at the American College of Cardiology 2026 (ACC.26) Scientific Sessions. Results presented at ACC.26 indicated 297 of the 1086 patients screened, or 27.3%, met the study definition for hypercortisolism. Among the subset of participants with hemoglobin A1c of 7.5% or higher who were taking 3 or more antihypertensive medications, the prevalence rose to 32.6%.

Investigators used the 1-mg overnight dexamethasone suppression test (DST), defining hypercortisolism as a post-DST cortisol greater than 1.8 μg/dL. Individuals with conditions confounding DST interpretation were excluded, and a historical eGFR below 30 mL/min/1.73 m² was exclusionary, though baseline eGFR was used for this analysis.

Among 1086 participants, 140 (12.9%) had an eGFR below 45 mL/min/1.73 m², 203 (18.7%) had an eGFR of 45 to 59 mL/min/1.73 m², and 743 (68.4%) had an eGFR of 60 mL/min/1.73 m² or higher. Hypercortisolism prevalence rose as kidney function declined, reaching 43.6% in the lowest eGFR subgroup, 30.0% in the middle subgroup, and 23.6% in the highest subgroup. The difference across groups was significant (

Kidney Function Markers and CKD Progression Risk by Hypercortisolism Status

Participants with hypercortisolism had a lower mean eGFR than those without hypercortisolism (63.8 vs 71.9 mL/min/1.73 m²; 

 < .0001). Mean urine albumin-to-creatinine ratio (UACR) trended higher in the hypercortisolism group (234.7 vs 139.9 mg/g; 

Hypercortisolism frequency also climbed across worsening chronic kidney disease (CKD) progression risk categories, with the highest prevalence in the very-high-risk group (

 < .0001 for any difference across groups). When further stratified, the proportion of participants with a post-DST cortisol above 1.8 μg/dL reached 49% at an eGFR below 30 mL/min/1.73 m² and 42% at 30 to 44 mL/min/1.73 m², compared with 22% at an eGFR of 90 mL/min/1.73 m² or higher.

Morning adrenocorticotropic hormone and post-DST cortisol values were broadly comparable across eGFR subgroups, though mean post-DST cortisol was modestly higher in participants with reduced renal function. The investigators noted the analysis could not determine whether the association reflects a true disruption of the hypothalamic-pituitary-adrenal axis or methodologic effects of the uremic state on cortisol measurement.

DeFronzo RA, Aroda VR, Basile JN, et al. Prevalence of endogenous hypercortisolism in individuals with resistant hypertension stratified by kidney function: results from the MOMENTUM study. Presented at: 10th Annual Heart in Diabetes Meeting; June 19-21, 2026. Abstract 0055.

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome. Corcept Therapeutics, Incorporated. Published June 17, 2026. Accessed June 21, 2026. 

https://ir.corcept.com/news-releases/news-release-details/corcept-resubmits-new-drug-application-relacorilant-treatment/

Campbell P. MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension. Hcplive.com. Published March 29, 2026. Accessed June 21, 2026. 

https://www.hcplive.com/view/momentum-hypercortisolism-present-in-1-in-4-with-resistant-hypertension

Articles

Endogenous hypercortisolism prevalence increased stepwise with declining renal function among adults with resistant hypertension in the US multicenter, prospective MOMENTUM study. Using a 1-mg overnight dexamethasone suppression test threshold of post-DST cortisol >1.8 μg/dL, hypercortisolism reached 43.6% at eGFR <45 versus 23.6% at eGFR ≥60 mL/min/1.73 m² (P<.0001). Hypercortisolism was associated with lower mean eGFR and numerically higher UACR, supporting targeted screening in higher CKD-risk strata.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

A trio of analyses from LIBERTY AD PEDS, LIBERTY AD PRESCHOOL, and the long-term PED-OLE extension study show dupilumab (Dupixent) improves growth attainment in school-age children, provides rapid caregiver-reported symptom relief in infants and toddlers, and sustains regional skin improvements across body regions for up to 3 years in children with 

Revolutionizing Atopic Dermatitis (RAD) 2026 Conference

, the analyses span the youngest patients in dupilumab's development program, from infants as young as 6 months through children aged 11 years, and document benefits ranging from improved height percentile gain to reduced caregiver burden during the first 2 weeks of treatment.

"Dupilumab treatment for up to 3 years demonstrated sustained efficacy across all anatomic regions in children aged 6 months to 11 years with moderate-to-severe AD, with safety consistent with the known safety profile of dupilumab," the PED-OLE investigators concluded.

Growth Improvement in Children 6-11 Years and Caregiver Impressions in Under-5s

In the LIBERTY AD PEDS growth analysis, children aged 6 to 11 years with severe AD who were below the 30th height percentile at baseline showed significantly greater height gain with dupilumab than placebo over 16 weeks. The proportion achieving at least a 5-percentile improvement in height-for-age was 31.9% with dupilumab versus 11.1% with placebo (

Logistic regression models confirmed the growth benefit remained significant after adjustment for cumulative topical corticosteroid (TCS) dose (Odds Ratio, 4.21; 95% CI, 1.40-12.63; 

= .010), indicating dupilumab's effect appears independent of reduced TCS use.

In LIBERTY AD PRESCHOOL, caregivers of infants and children aged 6 months to 5 years reported significantly better Caregiver Global Impression of Disease  scores, indicating no or mild symptoms, with dupilumab versus placebo from week 2, the earliest timepoint measured. By week 16, 51.8% of caregivers in the dupilumab group reported no or mild symptoms versus 5.5% with placebo.

On the Caregiver Global Impression of Change, 67.1% of caregivers in the dupilumab group rated symptoms as much better or moderately better at week 16 versus 11.2% with placebo (

<.0001), a difference of 55.9 percentage points.

The PED-OLE open-label extension (NCT02612454) enrolled children from both LIBERTY AD PRESCHOOL (ages 6 months to 5 years; N=180) and LIBERTY AD PEDS (ages 6-11 years; N=383), providing up to 152 weeks of continuous dupilumab data. The analysis examined EASI-75 and EASI-90 by anatomic region: head, trunk, upper extremities, and lower extremities.

In children aged 6 months to 5 years at week 52, EASI-90 response rates were 91.9% for head/neck, 81.8% for trunk, 85.4% for upper extremities, and 77.7% for lower extremities. In the 6-11 year age group at week 152, EASI-90 rates were 80.9% for head, 77.7% for trunk, 86.4% for upper extremities, and 75.3% for lower extremities.

Treatment-emergent adverse events led to permanent discontinuation in 1.1% of the younger cohort and 0.8% of the older cohort. Drug-related serious treatment-emergent adverse events were infrequent (0.6% and 0.3%).

Irvine AD, Paller AS, Siegfried EC, et al. Growth improvement in children 6 to 11 years with severe atopic dermatitis treated with dupilumab irrespective of TCS use. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Weibel L, Prajapati VH, Vainder E, et al. Caregiver impressions of disease and change in infants and children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Paller AS, Siegfried EC, Pinter A, et al. Long-term dupilumab treatment resulted in consistent improvements across anatomic regions in pediatric patients with moderate-to-severe atopic dermatitis. Presented at: Revolutionizing Atopic Dermatitis; Nashville, TN; June 17-19, 2026.

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Stephen Greene, MD, is an associate professor of medicine at Duke University School of Medicine and cardiologist at the Duke Clinical Research Institute in Durham, NC. Greene is a member of HCPLive's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Katherine Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington.

A 20-minute podcast discussuion around the nsMRA finerenone, FIND-CKD, and its role in the broader CKM landscape.

Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how 

 is measured, mechanistically understood, and treated across its many causes.

On an episode of Don't Miss a Beat recorded at the 

, hosts Stephen Greene, MD, meeting co-chair and heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation and cardiologist at Brigham and Women's Hospital, spoke with Katherine Tuttle, MD, professor of medicine at the University of Washington, about the phase 3 FIND-CKD trial and how it informs on the overall role of finerenone (Kerendia) in management of cardiovascular-kidney-metabolic syndrome.

FIND-CKD showed finerenone slowed total estimated glomerular filtration rate (eGFR) slope by 0.7 mL/min/1.73 m² per year versus placebo, irrespective of diagnosis. Much of the discussion focused less on the number and more on why it counts as clinically meaningful.

Drawing on CKD Prognosis Consortium data from hundreds of thousands of patients, Tuttle explained why eGFR slope reliably predicts kidney failure when a trial runs at least 2 years. CKD progresses rather than striking as a discrete event, so the field has moved toward endpoints measurable without waiting for organ failure or death.

On safety, hyperkalemia occurred more often with finerenone than placebo, about 12% versus 3%, though fewer than 1% of patients discontinued. The framing was practical, with background SGLT2 inhibition expected to lower the risk.

Mechanism anchors much of the conversation between Tuttle, Greene, and Vaduganathan. 

Tuttle highlighted how glomerular diseases, like 

, are immunologic disorders needing disease-specific therapy, yet all CKD converges on shared final common pathways of inflammation and fibrosis. Broad agents like finerenone target those pathways, making combination therapy the emerging model, pairing treatment of the inciting disease with control of progression.

The group also discussed the field’s trend toward precision nephrology. Protocol biopsies from the Kidney Precision Medicine Project showed only about half of patients labeled as diabetic CKD had classic diabetic nephropathy. A parallel to oncology followed, where deep phenotyping replaced uniform regimens, suggesting not every patient will need every drug.

Tuttle positioned finerenone alongside renin-angiotensin system inhibitors and SGLT2 inhibitors as an emerging pillar for non-diabetic CKD, with GLP-1 receptor agonists and endothelin antagonists possibly to come. A pooled analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showed roughly 30% reductions in kidney and cardiovascular outcomes and an 11% drop in all-cause mortality. The closing point held the cardiorenal patient often arrives through either specialty's door, making preservation of organ function and quality of life the shared aim.

Relevant disclosures for Tuttle include Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novo Nordisk, Roche, and Travere Therapeutics. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.

Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. 

Bayer. Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026. Bayer.com. Published June 2, 2026. Accessed June 21, 2026. 

https://www.bayer.com/en/us/news-stories/kerendia-in-non-diabetic-chronic-kidney-disease

Podcasts

Phase 3 FIND-CKD data show finerenone slows kidney function decline in non-diabetic chronic kidney disease, extending the agent's role beyond diabetic CKD.

Chronic Kidney Disease

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Don’t Miss a Beat

The Don't Miss a Beat Podcast is a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

 testing prevalence was just 1.1% among US adults, while a companion at-home screening program identified elevated LDL-C and/or lipoprotein(a) levels in nearly two-thirds of results returned.

Current dyslipidemia guidelines recommend lipoprotein(a) measurement at least once during adulthood, yet adoption of universal testing has lagged. In data presented at the 

, the Family Heart Foundation examined both sides of this gap: how often lipoprotein(a) is ordered in routine claims data, and what happens when free at-home testing removes the access barrier.

Lp(a) testing prevalence and racial disparities

Investigators analyzed the Family Heart Database, a claims and laboratory repository spanning 350 million US individuals from 2012 to 2024, to assess Lp(a) testing prevalence in adults tested during 2023 to 2024. Among all adults in the cohort (2,063,830 of 187,594,288), Lp(a) testing prevalence was 1.1%.

Prevalence rose to 2.6% among adults with a standard lipid profile, 2.8% among those with established 

 (ASCVD), and 5.7% among adults with both ASCVD and a lipid profile on record.

Diabetes (adjusted odds ratio [aOR], 0.78; 95% CI, 0.78 to 0.79; 

 < .0001) and stage III to V chronic kidney disease (aOR, 0.88; 95% CI, 0.87 to 0.89; 

 < .0001) were both associated with lower odds of Lp(a) testing relative to adults without those conditions. Greater Charlson Comorbidity Index scores followed a similar inverse pattern, with adults carrying a comorbidity index of 8 or more 26% less likely to be tested than those with no comorbidities (aOR, 0.74; 95% CI, 0.72 to 0.75; 

Repeat testing occurred in 25.1% (517,125 of 2,063,830) of adults with an initial Lp(a) result. In multivariable regression, familial hypercholesterolemia carried the strongest independent association with testing (aOR, 2.44; 95% CI, 2.38 to 2.49; 

 < .0001), followed by high LDL-C, non-statin lipid-lowering therapy, established coronary artery disease, and age over 40 years. White adults were 87% more likely to undergo Lp(a) testing than Black adults (aOR, 1.87; 95% CI, 1.85 to 1.88; 

 < .0001), a disparity investigators flagged as a target for intervention.

The Family Heart Foundation launched Cholesterol Connect in September 2024 to provide free at-home LDL-C and Lp(a) screening paired with Care Navigator support. According to the study, kit orders reached 30,950 through March 2026, outpacing the program's original projections. Among the first 8675 kits with results, 41% (3556) showed elevated LDL-C alone, 13% (1096) showed elevated LDL-C and Lp(a), and 11% (977) showed elevated Lp(a) alone.

User satisfaction, measured among 5,300 individuals who returned kits between March 2025 and March 2026, produced a Net Promoter Score of 73.8 against an industry benchmark range of -10 to 19. Respondents cited the program's free cost, simple process, and access to actionable health information as key drivers of satisfaction. 

Among adults who received an email invitation for 1-on-1 support after a high result, 15% engaged with a Care Navigator between November 2025 and March 2026.

Investigators on both posters called for strategies to close persistent testing gaps, including efforts to improve screening kit return rates and expand engagement with Family Heart Care Navigation.

Bardach SH, Brugger C, Hawke A, Wilemon K, MacDougall D, Paige H. Reducing gaps in cardiovascular risk factor awareness through free at-home LDL-C and lipoprotein(a) screening and support: insights from the first 30,950 tests ordered through the Family Heart Foundation Cholesterol Connect program. Presented at: 10th Annual Heart in Diabetes; June 19-21, 2026; Philadelphia, PA.

MacDougall DE, Baum S, Sperling L, Hartsuff B, Paige H, Wilemon KA. Prevalence and associated determinants of lipoprotein(a) testing in a contemporary cohort of US adults from the Family Heart Database. Presented at: 10th Annual Heart in Diabetes; June 19-21, 2026; Philadelphia, PA.

HCPLive. Updated ACC/AHA dyslipidemia guidelines incorporate LDL-C goals, Lp(a) focus, with Deepak Bhatt, MD, MPH. 

https://www.hcplive.com/view/updated-acc-aha-dyslipidemia-guidelines-incorporate-ldl-c-goals-lp-a-focus-with-deepak-bhatt-md-mph

. Published March 25, 2026. Accessed June 20, 2026.

Routine lipoprotein(a) [Lp(a)] testing remains rare in US adults despite guideline support for at-least-once lifetime measurement. Claims and laboratory data from 2012–2024 showed only 1.1% testing prevalence in 2023–2024, with modest enrichment in ASCVD and lipid-profile subgroups and lower testing odds in diabetes and advanced CKD. Marked racial disparities favored White adults. A free at-home LDL-C/Lp(a) program rapidly scaled, with nearly two-thirds of returned kits revealing elevated LDL-C and/or Lp(a), high user satisfaction, and limited uptake of navigator support.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults

This Q&A interview with Mona Shahriari, MD, highlights key atopic dermatitis tips, new developments, and themes from her session at RAD 2026.

Q&A: What Are the Most Exciting New Atopic Dermatitis Developments? With Mona Shahriari, MD

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Yale Study: Two-Thirds of Online GLP-1 Prescriptions Require No Clinician-Patient Interaction

Mona Shahriari, MD, spoke about the evolving understanding of atopic dermatitis as a systemic disease, the complexities of treatment selection, and more.

What is the Most Contested Issue in Atopic Dermatitis Today? With Mona Shahriari, MD

Multiple trials at RAD 2026 highlight the efficacy and safety of delgocitinib in chronic hand eczema. 

Delgocitinib Cream Shows Consistent CHE Efficacy Across Several Subgroups

RAD 2026 data indicate tralokinumab achieved significantly deeper hand eczema clearance and greater functional improvement than dupilumab in an indirect comparison.

RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC

Roflumilast cream data from RAD 2026 shed further light on the efficacy and safety across the age spectrum.

Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients

Pulmonary nurse practitioner at Prisma Health in Greenville, South Carolina, and president elect, Association of Pulmonary APPs (APAPP)

Sarah Tomashefski, MSN, says persistent myths about who gets AATD and a failure to screen patients with any obstructive lung disease are driving a diagnostic gap APPs are uniquely positioned to close.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

HCPLive convened an in-depth roundtable discussion on advancing biologic therapy for asthma and COPD in a complex real-world prescribing environment.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD

Harrison Nguyen, MD, MBA, MPH, is a double board-certified dermatologist/Mohs micrographic surgeon and clinical researcher in Houston, Texas.

Nguyen urges clinicians to consider patient's disease presentation, comorbidities, treatment goals, and preferences when making therapeutic decisions.

Individualizing Treatment Selection in Atopic Dermatitis, With Harrison Nguyen, MD, MBA, MPH

At RAD 2026, Nguyen speaks on key highlights from his “Medical Crossfire” session, touching on the atopic dermatitis treatment landscape.

Latest News

The Role of Aldosterone & Aldosterone Synthase Inhibitors in Cardiology, with Javed Butler, MD, MBA

MOMENTUM: Lower Kidney Function Could Signal Hypercortisolism in Resistant Hypertension

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

Don't Miss a Beat: Finerenone, FIND-CKD, and the Evolution of CKM, with Katherine Tuttle, MD

Lipoprotein(a) Testing Prevalence Remains Just 1.1% in US Adults